Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Acceleron

    - PMLiVE

    David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

    Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    - PMLiVE

    Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

    A new restructuring programme has been approved to support the initiative

    - PMLiVE

    MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

    Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

    - PMLiVE

    Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

    Cardiovascular diseases result in an estimated 17.9 million global deaths each year

    - PMLiVE

    MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

    Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

    - PMLiVE

    Merck and Daiichi Sankyo to jointly develop T-cell engager in deal worth over $170m

    The partners will evaluate MK-6070 as part of a combination treatment for small cell lung cancer

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

    More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

    - PMLiVE

    Merck’s Keytruda combination recommended by NICE for advanced gastric cancer

    More than 6,500 new cases of gastric cancer are diagnosed in the UK every year

    - PMLiVE

    Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants

    The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

    - PMLiVE

    ICR study reveals Lynparza could treat more advanced prostate cancer patients

    Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

    - PMLiVE

    Merck’s pulmonary arterial hypertension therapy receives CHMP recommendation

    Approximately 30,000 people in the EU are currently living with the rare blood disorder

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links